Galen Center urges Malaysian government to pass tobacco control bill

Nov.29.2022
Galen Center urges Malaysian government to pass tobacco control bill
The Galen Center urges Malaysia to pass the controversial tobacco control bill within the government's first 100 days.

On November 28th, the Galen Centre for Health and Social Policy in Kuala Lumpur called on the government of Anwar Ibrahim to propose and pass the controversial tobacco control bill within the first 100 days of his tenure.


Azrul Mohd Khalib, CEO of Galen Center, has revealed that significant progress has been made on the proposed Control of Tobacco Product and Smoking Bill 2022 after undergoing several revisions suggested by the bipartisan committee of the 14th Parliament's Dewan Rakyat. The Bill proposes a ban on smoking and e-cigarette use for those born in or after 2007, also known as an intergenerational ban.


Azrul, speaking on the radio program "Health and Life: Doctors at Home" last Friday, told BFM host Tee Shiao Eek, "This is an obvious outcome because it clearly shows how different parties from different viewpoints and ideologies can collaborate to develop a multiparty bill - not even just a two-party bill - and then pass it through a vote. This has already been laid out on the table, the work has been completed.


This was an easy victory. In fact, you can submit it to parliament and vote on it at the next meeting. This is a clear example of how we can come together, work collaboratively, and create something beneficial.


In other proposed amendments, the Parliamentary Special Select Committee (PSSC) led by then-Health Minister Khairy Jamaluddin agreed to lift the ban on tobacco or electronic cigarette products for those born after January 1, 2007, but decided to maintain the ban on smoking or using e-cigarettes and purchasing such products for this group.


The 14th Parliament's PSSC has also agreed to reduce the maximum fine for GEG violators from 5,000 Malaysian Ringgit (approximately 7,923 dollars) to 500 Malaysian Ringgit (approximately 792 dollars), and may potentially offer community service.


Prior to the dissolution of parliament last month, Khairy, who was then serving in the government of Ismail Sabri Yaakob, failed to bring the tobacco bill to a second reading and debate. This was due to serious concerns raised by several Pakatan Harapan (PH) lawmakers and human rights advocates over the broad enforcement powers, economic impact, and infringement on personal liberties inherent in the bill.


Prime Minister Anwar's coalition government now holds a two-thirds majority in the Dewan Rakyat, with the addition of the Sabah branch of the United Malays National Organization (UMNO) to the coalition made up of the National Front (BN) and the Sarawak United People's Party (GPS) led by the People's Justice Party (PH).


Azrul further urges the next Health Minister to submit a Health White Paper to Parliament or release a document outlining reforms to the healthcare system for the next 15 years.


Khairy previously established a 13-member advisory committee for the "Health White Paper," co-chaired by former Health Minister Dr. S. Subramaniam and Axiata Group Chairman Shahril Ridza Ridzuan. However, there was no formation of a Health Reform Committee to oversee the implementation of recommendations outlined in the yet-to-be-released "Health White Paper.


According to Azrul, "We have put in a lot of effort, work, and contributions in considering the introduction of healthcare reform into the Malaysian healthcare system, which is stated in the white paper. Many individuals have contributed with their forward-thinking and aspirations, and most importantly, they witness the change that is needed, even earlier than the previous health minister, going back 20 years. We hope that the next minister, whoever she or he may be, will take out the white paper, present it to parliament or publicize it, so we can use the recommendations in it. It is meaningless that nobody has seen or referenced the document in this article, as it has not been made public.


In his manifesto for the 15th election, PH pledged to establish a Health Committee to oversee the implementation of the national healthcare reform plan in conjunction with the Ministry of Economic Planning, Finance, Health, and Education. The aim is to address systemic issues such as healthcare financing, decentralization of power, and the public-private partnership.


Azrul urges the PH-led coalition government not to reinvent the wheel in healthcare reform. He stated, "The proposals put forth by Kairi during his tenure stem from years of experience from those who have worked in the department. What is important for us is to recognize that regardless of who initiated these ideas in the past, we should be able to examine them and give them the attention and value they deserve. We need to do this now. If we start from scratch, we will be wasting time." Azrul suggests that the next Health Minister's first 100 days in office should focus on low-hanging fruit initiatives.


Finally, he said, "It's important to talk to people and listen to their voices. When taking office, you may have your own ideas, but I, honestly, will talk to people from the Ministry of Health, as well as other departments, and most importantly, talk to patients and patient groups. They can tell you what can be done during this time and what can be achieved.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
Product | DOJO Launches BLAST10K Fresh in UK With 0+10ml E-Liquid Structure, Retaining 2+8ml Pod Compatibility
DOJO launched the BLAST10K Fresh in the UK on September 4, 2026, introducing its INSTA-JUICED™ technology and a new 0+10ml structure that keeps e-liquid separated from the coil before activation. The device features a 1000mAh rechargeable battery, COREX BLAST dual-mesh technology and SSS leak-resistant technology, with a manufacturer-rated capacity of up to 10,000 puffs. It also retains compatibility with existing 2+8ml pods across the BLAST ecosystem. The launch introduces eight new flavors, including Matcha Strawberry, which DOJO describes as an industry first.
Market
Sep.04